DE602004006618D1 - Azaindolverbindungen als kinaseinhibitoren - Google Patents
Azaindolverbindungen als kinaseinhibitorenInfo
- Publication number
- DE602004006618D1 DE602004006618D1 DE602004006618T DE602004006618T DE602004006618D1 DE 602004006618 D1 DE602004006618 D1 DE 602004006618D1 DE 602004006618 T DE602004006618 T DE 602004006618T DE 602004006618 T DE602004006618 T DE 602004006618T DE 602004006618 D1 DE602004006618 D1 DE 602004006618D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- kinaseinhibitors
- azaindol
- methods
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0301372 | 2003-05-09 | ||
SE0301372A SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Novel compounds |
PCT/SE2004/000696 WO2004099205A1 (en) | 2003-05-09 | 2004-05-06 | Azaindole compounds as kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE602004006618D1 true DE602004006618D1 (de) | 2007-07-05 |
DE602004006618T2 DE602004006618T2 (de) | 2008-01-31 |
Family
ID=20291270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004006618T Expired - Fee Related DE602004006618T2 (de) | 2003-05-09 | 2004-05-06 | Azaindolverbindungen als kinaseinhibitoren |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060287354A1 (de) |
EP (1) | EP1625127B1 (de) |
JP (1) | JP2006525998A (de) |
CN (1) | CN1784403A (de) |
AT (1) | ATE362932T1 (de) |
AU (1) | AU2004236146B2 (de) |
BR (1) | BRPI0410117A (de) |
CA (1) | CA2523922A1 (de) |
DE (1) | DE602004006618T2 (de) |
ES (1) | ES2286634T3 (de) |
MX (1) | MXPA05012026A (de) |
SE (1) | SE0301372D0 (de) |
WO (1) | WO2004099205A1 (de) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
ATE524467T1 (de) | 2005-04-25 | 2011-09-15 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
MX2007014619A (es) | 2005-05-20 | 2009-02-13 | Vertex Pharma | Pirrolopiridinas de utilidad como inhibidores de proteina quinasa. |
CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
KR20080026654A (ko) * | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
EP1926735A1 (de) | 2005-09-22 | 2008-06-04 | Incyte Corporation | Tetracyclische inhibitoren von januskinasen |
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
EP1979353A2 (de) * | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Kondensierte heterobizyklische kinaseinhibitoren |
CA2643863A1 (en) * | 2006-04-07 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
JP5448164B2 (ja) | 2006-07-28 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を変調する化合物 |
MX2009002888A (es) | 2006-09-25 | 2009-03-31 | Boehringer Ingelheim Int | Compuestos que modulan el receptor cb2. |
US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
MX2009007426A (es) * | 2007-01-12 | 2009-07-17 | Astellas Pharma Inc | Compuesto de piridina condensado. |
ES2431815T3 (es) | 2007-04-11 | 2013-11-28 | Kissei Pharmaceutical Co., Ltd. | Derivado de (aza)indol y uso del mismo para fines médicos |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
EP3495369B1 (de) | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Verwendung von salzen des janus-kinasehemmers (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitril |
JP5492092B2 (ja) | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
CA2704599C (en) | 2007-11-16 | 2015-05-12 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
SI2288610T1 (sl) | 2008-03-11 | 2016-11-30 | Incyte Holdings Corporation | Derivati azetidina in ciklobutana kot inhibitorji jak |
CA2722326A1 (en) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
US8178568B2 (en) | 2008-07-10 | 2012-05-15 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the CB2 receptor |
AU2009296838A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which selectively modulate the CB2 receptor |
WO2010058846A1 (ja) * | 2008-11-21 | 2010-05-27 | アステラス製薬株式会社 | 4,6-ジアミノニコチンアミド化合物 |
WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
WO2010093808A1 (en) | 2009-02-11 | 2010-08-19 | Reaction Biology Corp. | Selective kinase inhibitors |
MX2011012262A (es) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak). |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
EP2443107B1 (de) | 2009-06-16 | 2018-08-08 | Boehringer Ingelheim International GmbH | Azetidin 2 -carboxamidderivate als cb2-rezeptormodulatoren |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
CA2767079A1 (en) | 2009-07-08 | 2011-01-13 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
PT2486041E (pt) | 2009-10-09 | 2013-11-14 | Incyte Corp | Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo |
WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
JP5746228B2 (ja) | 2010-03-05 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節するテトラゾール化合物 |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
JP5746764B2 (ja) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
CN103298817A (zh) * | 2011-01-07 | 2013-09-11 | 利奥制药有限公司 | 作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途 |
WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
AU2012232658B2 (en) | 2011-03-22 | 2016-06-09 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
EP2741747A1 (de) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | Jak-/p13k-mtor-kombinationstherapie |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
JP2015529242A (ja) | 2012-09-21 | 2015-10-05 | アドヴィヌス セラピューティクス リミテッドAdvinus Therapeutics Limited | 置換された縮合三環式化合物、組成物およびその医薬用途 |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
EA030705B1 (ru) | 2013-03-06 | 2018-09-28 | Инсайт Холдингс Корпорейшн | Способы и промежуточные соединения при получении ингибитора jak |
EP2803668A1 (de) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole |
ES2792549T3 (es) | 2013-08-07 | 2020-11-11 | Incyte Corp | Formas de dosificación de liberación sostenida para un inhibidor de JAK1 |
KR101548492B1 (ko) | 2013-09-23 | 2015-09-01 | 건국대학교 산학협력단 | 야누스 키나아제 1 (Janus kinase 1)의 활성을 선택적으로 저해하는 4-아미노-7-아자인돌-5-카르복사마이드 유도체 |
WO2015119126A1 (ja) * | 2014-02-04 | 2015-08-13 | 大鵬薬品工業株式会社 | アザインドール誘導体 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
WO2016047678A1 (ja) * | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
US10045981B2 (en) | 2015-11-24 | 2018-08-14 | Jakpharm, Llc | Selective kinase inhibitors |
CN107513067A (zh) | 2016-06-16 | 2017-12-26 | 北京赛林泰医药技术有限公司 | 含有取代环戊基的吡咯并嘧啶化合物 |
WO2018140648A1 (en) | 2017-01-25 | 2018-08-02 | Eric Jon Jacobsen | Pyrrolopyrimidine itk inhibitors for treating inflammation and cancer |
US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
BR112020008850A2 (pt) | 2017-11-03 | 2020-10-20 | Aclaris Therapeutics, Inc. | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
PL3746429T3 (pl) | 2018-01-30 | 2022-06-20 | Incyte Corporation | Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu) |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
EP3833350A4 (de) | 2018-08-10 | 2022-05-18 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidin-itk-hemmer |
CN113874015A (zh) | 2018-12-21 | 2021-12-31 | 细胞基因公司 | Ripk2的噻吩并吡啶抑制剂 |
WO2020182159A1 (zh) * | 2019-03-14 | 2020-09-17 | 上海华汇拓医药科技有限公司 | Jak激酶抑制剂及其制备方法和在医药领域的应用 |
JP2022531088A (ja) | 2019-05-02 | 2022-07-06 | アクラリス セラピューティクス,インコーポレイテッド | Jak阻害剤としての置換ピロロピリジン |
KR20220107213A (ko) | 2019-11-22 | 2022-08-02 | 인사이트 코포레이션 | Alk2 억제제 및 jak2 억제제를 포함하는 병용 요법 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2687402B1 (fr) * | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
US5389509A (en) * | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
US6686374B1 (en) * | 1999-08-12 | 2004-02-03 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
CN1615873A (zh) * | 1999-12-24 | 2005-05-18 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
SE0202463D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-05-09 SE SE0301372A patent/SE0301372D0/xx unknown
-
2004
- 2004-05-06 JP JP2006508046A patent/JP2006525998A/ja active Pending
- 2004-05-06 US US10/556,227 patent/US20060287354A1/en not_active Abandoned
- 2004-05-06 AU AU2004236146A patent/AU2004236146B2/en not_active Ceased
- 2004-05-06 CN CNA2004800126269A patent/CN1784403A/zh active Pending
- 2004-05-06 MX MXPA05012026A patent/MXPA05012026A/es active IP Right Grant
- 2004-05-06 CA CA002523922A patent/CA2523922A1/en not_active Abandoned
- 2004-05-06 WO PCT/SE2004/000696 patent/WO2004099205A1/en active IP Right Grant
- 2004-05-06 ES ES04731527T patent/ES2286634T3/es active Active
- 2004-05-06 AT AT04731527T patent/ATE362932T1/de not_active IP Right Cessation
- 2004-05-06 DE DE602004006618T patent/DE602004006618T2/de not_active Expired - Fee Related
- 2004-05-06 EP EP04731527A patent/EP1625127B1/de not_active Not-in-force
- 2004-05-06 BR BRPI0410117-0A patent/BRPI0410117A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2004236146B2 (en) | 2007-12-13 |
AU2004236146A1 (en) | 2004-11-18 |
EP1625127A1 (de) | 2006-02-15 |
MXPA05012026A (es) | 2006-02-03 |
ES2286634T3 (es) | 2007-12-01 |
ATE362932T1 (de) | 2007-06-15 |
EP1625127B1 (de) | 2007-05-23 |
SE0301372D0 (sv) | 2003-05-09 |
JP2006525998A (ja) | 2006-11-16 |
US20060287354A1 (en) | 2006-12-21 |
BRPI0410117A (pt) | 2006-05-23 |
DE602004006618T2 (de) | 2008-01-31 |
WO2004099205A1 (en) | 2004-11-18 |
CN1784403A (zh) | 2006-06-07 |
CA2523922A1 (en) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE362932T1 (de) | Azaindolverbindungen als kinaseinhibitoren | |
SE0101675D0 (sv) | Novel composition | |
SE0301373D0 (sv) | Novel compounds | |
ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
EA200970156A1 (ru) | Пиридизиноновые производные | |
ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
EA200800546A1 (ru) | Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk) | |
HRP20070043A2 (en) | Antiviral compounds | |
ATE378337T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
ATE420879T1 (de) | Indolizine als kinaseproteinhemmer | |
EA200700188A1 (ru) | Производные замещенного 2-алкилхиназолинона как ингибиторы parp | |
DK1682530T3 (da) | Pyrrolsubstituerede indoler som inhibitorer af PAI-1 | |
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
TW200609221A (en) | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | |
EA201071224A1 (ru) | Ингибиторы limk2, композиции, содержащие их, и способы их применения | |
EA201001481A1 (ru) | Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4 | |
EA200801414A1 (ru) | Кальцилитические соединения | |
EA200800393A1 (ru) | Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат | |
ATE430148T1 (de) | Neue pyrrolodihydroisochinoline als pde10- inhibitoren | |
RS79703A (en) | Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors | |
BRPI0417205A (pt) | composições farmacêuticas | |
ATE394386T1 (de) | 2-phenylpyran-4-on-derivate als selektive cox-2 inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |